Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Terminated 2Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1FED 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 42Tumor-Agnostic 19Thoracic 5Genitourinary 4Sarcoma 3Head & Neck 3Gynecologic 3Endocrine 2Dermatologic 2CNS 2NET 1Breast 1

Conditions

Head and Neck Neoplasms 13Squamous Cell Carcinoma of Head and Neck 8Nasopharyngeal Neoplasms 5Carcinoma, Non-Small-Cell Lung 4Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Ovarian Neoplasms 3Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Salivary Gland Neoplasms 2Recurrence 2Osteosarcoma 2Optic Nerve Glioma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Neoplasm Metastasis 2Melanoma 2Familial ependymoma 2Esophageal Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Renal Cell 2Astrocytoma 2Wilms Tumor 1Thyroid Neoplasms 1Testicular Neoplasms 1Teratoma 1Spinocerebellar Degenerations 1

Interventions

pembrolizumab 33Cetuximab 16Cisplatin 10Radiotherapy 8Paclitaxel 8Docetaxel 8atezolizumab 7Fluorouracil 7cemiplimab 6Drug Therapy 6budigalimab 5Gemcitabine 5Cyclophosphamide 5Blood Specimen Collection 5trametinib 4Pemetrexed 4Nivolumab 4Magnetic Resonance Spectroscopy 4Bleomycin 4Bevacizumab 4palbociclib 3fludarabine 3durvalumab 3dabrafenib 3avelumab 3Trastuzumab 3Oxaliplatin 3Interleukin-2 3Indocyanine Green 3Immunotherapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasms × Oxaliplatin × Head & Neck × Clear all
NCT05704985 2025-05-29

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

DEKA Biosciences

Phase 1 Active not recruiting
39 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Neoplasms, Pancreatic Neoplasms, Skin Neoplasms, Colorectal Neoplasms

NCT00591149 2017-06-14

Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer

University of Kansas Medical Center

Phase 2 Terminated
16 enrolled 5 charts
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasms, Neoplasms, Squamous Cell

NCT00557206 2013-11-05

Oxaliplatin and Docetaxel for Recurrent or Metastatic Head and Neck Cancer

Minneapolis Veterans Affairs Medical Center

Phase 2 Terminated
35 enrolled
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡